The relationship between disease severity and health care utilization has been estimated in several released analyses drawing on routine data. in four areas of model development: initial response to treatment; long-term disease progression; lifetime costs and benefits; and model structure. Consensus was also achieved Adipor2 on some key parameters such as choices of outcome measures, methods for extrapolation beyond trial data, and treatment switching. A research plan to support further consensus was also recognized. == Summary == Consensus guidance that fully reflects current evidence and clinical understanding was gained successfully. In addition , research needs have been identified. Such guidance can be updated because evidence evolves and policy questions modify and need not be prescriptive as long as deviations from consensus are clearly explained and justified. == Funding == Arthritis Research UK and the UK Medical Research Council Network of Hubs intended for Trials Methodology Research. == Electronic supplementary material == The online edition of this article (doi: 10. 1007/s40744-015-0020-0) contains supplementary material, which is available to certified users. Keywords: Arthritis, Biologics, Economic models == Intro == Biologic therapies symbolize a recent addition to treatments intended for inflammatory MRTX1257 joint diseases such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). While their efficacy continues to be established in a number of clinical trials and cost-effectiveness demonstrated in a number of assessments [1, 2], the evidence base is still associated with substantial uncertainty, and this poses a considerable challenge intended for decision-making in defining the role of different agents in the sequence of disease-modifying drugs used to manage these chronic diseases. A workshop to explore these difficulties took place in 2010, the proceedings of which were disseminated in a series of MRTX1257 papers [310]. A key finding of the workshop was that, despite the importance of economic models in guiding policy on the ownership of biologic therapies, there was no clear consensus on how the models should be structured, how they should be informed from data, and even which data were the most appropriate. Moreover, the differences between the models were sufficiently substantial to lead to contradictory recommendations. If consensus sights were available beforehand around the desirable properties MRTX1257 of the economic model, and the data sources that should inform it, this would assist model development and review to inform future policy decisions. With this in mind, a Consensus Working Party on decision models MRTX1257 intended for biologic therapies in RA and PsA was formed to identify the current scope for consensus, and identify gaps in the evidence base where further research is needed to support long term consensus. == Methods == The working party was set up to bring with each other key expertise as comprehensively as possible. Attendees included leading clinical specialists, health economists involved in the development of the main existing cost-effectiveness models that have informed policy making in the UK, and key individuals from Wellness Technology Assessment organizations and significant funders of research (Table1). Their remit was to: (1) frame and clarify the issues for which consensus needs to be sought; (2) set out, where possible, initial recommendations for consensus approaches intended for models, based on sound methodology, clinical judgment, and decision-maker preferences; and (3) set out an agenda intended for the research needed to achieve consensus where existing evidence is inconclusive. Four main topic areas intended for consensus were identified, with specific issues to address for each area (Table2). Further details of these issues, and their representation in existing models, are presented elsewhere [8]. == Table 1 . == Users of the Consensus Working Party BRAMBirmingham Rheumatoid Arthritis Model, DSUDecision Support Unit, EULAR European League Against Rheumatism, GRAPPA Group intended for Research and Assessment of MRTX1257 Psoriasis and Psoriatic Arthritis, NICE National Institute intended for Health and Treatment Excellence, NOARNorfolk Arthritis Register, PENTAGPeninsular.